8-K: NeuroMetrix Acquired by electroCore in Merger Completion

NeuroMetrix, Inc. has been acquired by electroCore, Inc. through a merger completed on May 1, 2025, making NeuroMetrix a wholly-owned subsidiary of electroCore.

Summary

• NeuroMetrix, Inc. has completed its merger with Nexus Merger Sub Inc., a subsidiary of electroCore, Inc., effective May 1, 2025.
• As a result of the merger, NeuroMetrix is now a wholly-owned subsidiary of electroCore.
• Each share of NeuroMetrix common stock was converted into the right to receive $4.49 in cash and one contingent value right (CVR).
• Preferred stock will remain outstanding but will no longer be convertible into common stock, instead converting into the right to receive the merger consideration payable for the common stock it would have been convertible into.
• Outstanding and unvested restricted stock awards were converted into the right to receive cash and CVRs.
• Options to purchase common stock that were unvested vested in full, with options having an exercise price below $4.49 receiving cash and a CVR, while options with an exercise price at or above $4.49 were cancelled with no consideration.
• Outstanding restricted stock units were cancelled and converted into the right to receive cash and CVRs.
• The company's Employee Stock Purchase Plan was terminated upon completion of the merger.
• Trading of NeuroMetrix common stock on the Nasdaq Capital Market was suspended on May 2, 2025, and the company will be delisted.
• The company intends to terminate the registration of all company securities and suspend its reporting obligations under the Exchange Act.
• Shai N. Gozani, David Van Avermaete, David E. Goodman, Joshua Horowitz and Nancy E. Katz ceased to be members of the Board of Directors.
• Dan Goldberger and Joshua Lev became the directors of the surviving corporation, with Dan Goldberger as CEO and Joshua Lev as CFO.
• The Surviving Corporation adopted the Fourth Amended and Restated Certificate of Incorporation and the Amended and Restated Bylaws.
• Contingent payments under the CVR agreement are tied to proceeds from the sale of Quell products and additional proceeds from asset purchase agreements with Fukuda Denshi Co., Ltd., Alera Medtech LLC and Impulse Medical Technologies.
• Holders of CVRs will also be entitled to receive an amount equal to $125,000 less any funds used by the Company as of July 1, 2025 out of a reserve of $250,000 for payment of potential expenses of the Company that were reserved against Net Cash and an amount equal to the remaining balance of the Reserve as of May 1, 2027.
• The CVR agreement term ends on the earlier of December 31 of the calendar year in which all distributions are paid or December 31, 2030.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The merger provides immediate cash value to shareholders but also introduces uncertainty regarding the future value of the CVRs and the integration process.

Positives

• Shareholders received $4.49 per share in cash, providing immediate value.
• Shareholders also received a Contingent Value Right (CVR), offering potential for additional payments based on future product sales and asset purchase agreements.
• The merger provides NeuroMetrix with the resources and support of a larger company, electroCore.

Negatives

• NeuroMetrix common stock has been delisted from the Nasdaq Capital Market.
• Former directors and officers have departed from the company.
• The future value of the CVR is uncertain and dependent on the performance of Quell products and the success of asset purchase agreements.

Risks

• The value of the CVRs is contingent on future events and may not result in any additional payments to shareholders.
• Integration of NeuroMetrix into electroCore could present challenges.
• The success of the Quell product line and asset purchase agreements is subject to market conditions and other factors.

Future Outlook

The future performance of the acquired company and the value of the CVRs are dependent on the success of the Quell product line and the proceeds from the Disposition Agreements.

Industry Context

This acquisition reflects a trend of consolidation in the medical device industry, where larger companies acquire smaller, innovative firms to expand their product portfolios and market reach.

Comparison to Industry Standards

• Comparable acquisitions in the medical device space often involve a combination of upfront cash payments and contingent value rights tied to future performance.
• The $4.49 per share cash consideration provides immediate value to shareholders, while the CVR offers potential upside based on the success of the Quell product line.
• Similar deals include the acquisition of [Hypothetical Company A] by [Hypothetical Company B], where a similar structure was used to bridge valuation gaps and align incentives.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders received cash and CVRs in exchange for their shares.
• Employees may experience changes as a result of the integration with electroCore.
• Customers may see changes in product offerings and support as a result of the acquisition.
• Suppliers and creditors will need to adapt to the new ownership structure.

Next Steps

• NeuroMetrix will be integrated into electroCore as a wholly-owned subsidiary.
• The company will file a Notification of Removal from Listing and/or Registration on Form 25 to delist and deregister the shares of the Company common stock.
• The company intends to file with the SEC a certification on Form 15 terminating the registration of all Company securities registered under Section 12(g) of the Exchange Act, and requesting that the Company's reporting obligations under Sections 13 and 15(d) of the Exchange Act be suspended.
• Distributions will be made to CVR holders based on the proceeds from the sale of Quell products and additional proceeds received under the Disposition Agreements.

Key Dates

Keywords

merger, acquisition, NeuroMetrix, electroCore, contingent value right, delisting, Quell, Net Cash